High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport.

By A. Eckardstein, J. Nofer, G. Assmann. Arteriosclerosis, Thrombosis and Vascular Biology, 2001

719 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Diabetic dyslipidaemia: from basic research to clinical practice* (2003, background): “Whether insulin or insulin resistance also influences the expression of these gate-keeper proteins of cholesterol trafficking (ABCA-1, SR-BI) as well as the precise mechanism of action are the exciting targets of future research.”
Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. (2004, positive): “RCT is a complex process that involves transporters in peripheral tissues and liver, enzymes and transfer proteins in the serum, receptors in the liver, the synthesis of bile acids in the liver, and the secretion of cholesterol and bile acids into the bile (160, 161).”
Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis (2006, background): “These small HDL precursors are produced as nascent HDL by the liver or intestine, are also released as surface fragments from lipolysed TG-rich lipoproteins (VLDL and chylomicrons), and finally may be generated during the interconversion of HDL3 and HDL2 (von Eckardstein et al., 2001).”